Literature DB >> 2969867

Proliferative and/or cytotoxic activity of lymphocyte clones to autologous human melanoma.

G Fossati1, A Anichini, P Squarcina, A Mazzocchi, G Parmiani.   

Abstract

Peripheral blood lymphocytes (PBL) of a patient with metastatic melanoma were cultured with autologous melanoma cells (Auto-Me) and recombinant interleukin 2 (IL-2) (MLTC-PBL). Thirty-five days later, when no cytotoxicity against Auto-Me or K562 was detectable, MLTC-PBL were cloned in the presence of Auto-Me, IL-2 (25 U/ml) and Daudi cells as feeder. Eighty-one growing clones were simultaneously screened for proliferative and cytotoxic activity to Auto-Me. Twenty-two clones proliferated in the presence of Auto-Me only, 29 in the presence of IL-2 only and 41 in the presence of Auto-Me plus IL-2; 12 clones showed cytotoxic activity against Auto-Me. Six clones expressed both cytotoxic and proliferative activity to Auto-Me. The phenotype of 6 proliferative clones tested was CD3+, CD4+, WT31+, CD8-, CD16-, Leu19-, whereas that of 2 cytotoxic-proliferative clones tested was CD3+, CD8+, Leu19+, WT31+, CD4-, CD16-. Specificity analysis of proliferative response of 6 clones and of cytotoxicity of 7 clones, tested on a panel of 14 different target cells, revealed a complex pattern of reactivity, each clone expressing a peculiar specificity. Our results suggest the possibility of isolating, from melanoma patients' PBL, T-cell clones with proliferative activity to Auto-Me and Auto-Me plus IL-2, and T-cell clones which apparently express both proliferative and cytotoxic activity to Auto-Me.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2969867     DOI: 10.1002/ijc.2910420216

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Cancer patients' lymphocytes contain CD3+ CD4+ cells that proliferate in response to autologous tumor cells in the presence of exogenous low-dose interleukin-2 and autologous accessory cells.

Authors:  M Radrizzani; M Quaia; B Benedetti; S Andreola; M Vaglini; E Galligioni; G Fossati; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Human recombinant IL-4 decreases the emergence of non-specific cytolytic cells and favours the appearance of memory cells (CD4+CD45RO+) in the IL-2-driven development of cytotoxic T lymphocytes against autologous ovarian tumour cells.

Authors:  A D Roth; S Dupuis; P Alberto
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

3.  T cell recognition of melanoma antigens in association with HLA-A1 on allogeneic melanoma cells.

Authors:  Q Chen; M Smith; T Nguyen; D W Maher; P Hersey
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

Review 4.  Human autologous tumor-specific T cells in malignant melanoma.

Authors:  C D Platsoucas
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

5.  Generation of cytotoxic effector cells against human melanoma.

Authors:  S P Leong; Y M Zhou; M E Granberry; T F Wang; T M Grogan; C Spier; R White; A Mehta; A Y Lin
Journal:  Cancer Immunol Immunother       Date:  1995-06       Impact factor: 6.968

6.  A phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma.

Authors:  A Ravaud; E Legrand; M M Delaunay; E Bussières; V Coulon; L Cany; S Huet; D Verdier; M Kind; F Chomy
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.